(19S)-8-[(dimethylamino)methyl]-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione;hydroxyurea

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 喜树碱
• 英文名称: (19S)-8-[(dimethylamino)methyl]-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione;hydroxyurea
• 化学式: C24H27N5O7
• 分子量: 497.5
• InChiKey: OXINQECJYWCQCO-BQAIUKQQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.89
• 重原子数：
  36
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  179
• 氢给体数：
  5
• 氢受体数：
  9

文献信息

• METHODS AND DEVICES FOR ENDOVASCULAR THERAPY
  申请人：Wallace Michael P.

  公开号：US20140142494A1

  公开（公告）日：2014-05-22

  The present invention provides methods and devices for treating endovascular disease. Vibrational energy is delivered to change compliance and increase permeability at the treatment area. To improve clinical outcomes, one or more therapeutic drugs may be delivered to the treatment area.
• US9375223B2
  申请人：——

  公开号：US9375223B2

  公开（公告）日：2016-06-28